Use of combination of probiotic and metagen for ameliorating conditions associated with SARS-CoV-2 infection
Through the combination of live Bacillus coagulis and heat-inactivated Lactobacillus plantarum, the lung inflammation and immune abnormalities caused by SARS-CoV-2 infection were solved, and effective improvements in the related conditions of SARS-CoV-2 infection were achieved. , avoid negative effects on normal immune function.
Patent Information
- Application Number
- CN202310870474.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2023-07-17
- Publication Date
- 2024-12-03
AI Technical Summary
Pulmonary inflammation, lung injury and immune abnormalities caused by SARS-CoV-2 infection are difficult to effectively improve, and the prior art may have negative effects on normal immune function.
Using the combination of live Bacillus coagulans CB85 and heat-inactivated Lactobacillus plantarum CB102, the bacterial number ratio is in the range of 1:0.1 to 1:10, as a food or pharmaceutical composition, To improve the conditions related to SARS-CoV-2 infection.
Significantly improves SARS-CoV-2-induced lung inflammation and immune abnormalities, and is better than the use of live Bacillus coagulis or Lactobacillus plantarum alone, reducing the risk of impaired lung function and immune storms, and providing more effective therapeutic effects.
Smart Images

Figure CN119054926A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the use of a combination of probiotics and postbiotics to improve disorders associated with SARS-CoV-2 infection, wherein the combination comprises live Bacillus coagulans CB85 (DSM 33893) and heat-killed Lactobacillus plantarum CB102 (DSM 33894). Background Art
[0002] Coronavirus disease 2019 (COVID-19) is an acute respiratory disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 causes an uncontrolled inflammatory response, releasing large amounts of pro-inflammatory cytokines and leading to lymphopenia, lymphocyte dysfunction, and granulocyte and monocyte abnormalities. If the virus stays in the body for too long, it may lead to an exaggerated and prolonged immune response (also known as a cytokine storm), which may cause lung injury, pneumonia, and acute respiratory distress syndrome (ARDS), or develop into chronic obstructive pulmonary disease (COPD).
[0003] In addition, some COVID-19 patients may even develop multisystem inflammatory syndrome (MIS), which causes severe inflammation of multiple organs. In severe cases, it may affect cardiovascular function and lead to acute heart failure (AHF), shock or death.
[0004] Therefore, researchers in this technical field are committed to finding ways to improve the abnormal inflammatory and immune responses induced by SARS-CoV-2 without negatively affecting normal immune function. Summary of the invention
[0005] In the present invention, the applicant has found that the combined use of live Bacillus coagulans CB85 (DSM 33893) and heat-killed Lactobacillus plantarum CB102 (DSM 33894) can effectively improve SARS-CoV-2-induced lung inflammation and lung injury and immune abnormalities. Therefore, the combination is expected to be applicable to improving the disorder associated with SARS-CoV-2 infection.
[0006] Therefore, in a first aspect, the present invention provides a combination of probiotics and postbiotics for use in preparing a composition for improving conditions associated with SARS-CoV-2 infection, wherein the combination comprises live Bacillus coagulans CB85 and heat-killed Lactobacillus plantarum CB102.
[0007] In a second aspect, the present invention provides a method for ameliorating conditions associated with SARS-CoV-2 infection, comprising administering a combination as described above to a subject in need thereof.
[0008] Preferably, the bacterial count ratio of Bacillus coagulans CB85 to Lactobacillus plantarum CB102 is in a range of 1:0.1 to 1:10.
[0009] Preferably, the condition associated with SARS-CoV-2 infection is selected from the group consisting of: lung inflammation, lung damage, lymphocytopenia, granulocyte abnormalities, immune escape, immune storm, multisystem inflammatory syndrome, and combinations thereof.
[0010] Preferably, the composition is a food composition.
[0011] Preferably, the composition is a pharmaceutical composition.
[0012] More preferably, the pharmaceutical composition is in a dosage form for oral administration.
[0013] Information on the deposit of biological materials
[0014] Deposit number: DSM 33893
[0015] Classification name: Bacillus coagulans CB85
[0016] Date of deposit: June 9, 2021
[0017] Depository: German Collection of Microorganisms
[0018] Address of the depository: D-38124 Braunschweig, 7B Yinhe Finscher, Germany
[0019] Deposit number: DSM 33894
[0020] Classification name: Lactobacillus plantarum CB102
[0021] Date of deposit: June 9, 2021
[0022] Depository: German Collection of Microorganisms
[0023] Address of the depository: D-38124 Braunschweig, 7B Yinhe Finscher, Germany BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The present invention is described in detail below in conjunction with the accompanying drawings and embodiments, so the above and other objects and features of the present invention can be more apparent by referring to the following description, the claims attached hereto and the accompanying drawings, in which:
[0025] Figures 1 to 3 The changes of Penh, EF50 and Rpef measured in each group of mice in Example 1 over time are shown respectively, wherein the English letters represent the statistical analysis results, if any of the English letters are the same between the two groups, it means there is no statistical significance, and if there are no identical English letters between the two groups, it means there is statistical significance (p<0.05);
[0026] Figures 4 to 8 The total white blood cell, lymphocyte, neutrophil, eosinophil and basophil contents measured in the bronchoalveolar lavage fluid (BALF) of each group of mice in Example 1 are shown respectively, wherein the English letters represent the statistical analysis results, and if any of the English letters are the same between the two groups, it means that there is no statistical significance, and if there are no identical English letters between the two groups, it means that there is statistical significance (p<0.05);
[0027] Figures 9 to 12The concentrations of IFN-γ, IL-4, IL-17 and IFN-β measured in the BALF of each group of mice in Example 1 are shown respectively, wherein the letters represent the statistical analysis results, and if any of the letters are the same between the two groups, it means that there is no statistical significance, and if there are no letters that are the same between the two groups, it means that there is statistical significance (p<0.05); and
[0028] Fig.13 The figure shows the pathological scores of the lung tissues of the mice in each group in Example 1 observed by hematoxylin-eosin staining, wherein the English letters represent the statistical analysis results. If any of the English letters are the same between the two groups, it means there is no statistical significance. If there are no identical letters between the two groups, it means there is statistical significance (p<0.05). DETAILED DESCRIPTION
[0029] For the purposes of this specification, it will be expressly understood that the term "comprising" means "including but not limited to," and that the term "comprises" has a corresponding meaning.
[0030] Unless otherwise defined, all technical and scientific terms used in this article have the meaning commonly understood by those skilled in the art in the field of the present invention. Those skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used to implement the present invention. Of course, the present invention is in no way limited to the methods and materials described.
[0031] The present invention provides a combination of probiotics and postbiotics for use in preparing a composition for improving a disorder associated with SARS-CoV-2 infection, wherein the combination comprises live Bacillus coagulans CB85 (DSM 33893) and heat-killed Lactobacillus plantarum CB102 (DSM 33894).
[0032] Preferably, the bacterial count ratio of Bacillus coagulans CB85 to Lactobacillus plantarum CB102 is in a range of 1:0.1 to 1:10. In a preferred embodiment of the present invention, the bacterial count ratio of Bacillus coagulans CB85 to Lactobacillus plantarum CB102 is 1:1.47.
[0033] As used herein, the terms "heat inactivation," "heat-killing," and "tyndallization" are used interchangeably and mean killing probiotics by heat treatment for a predetermined period of time.
[0034] According to the present invention, the heat-inactivated Lactobacillus plantarum CB102 can be prepared by techniques well known and commonly used by those skilled in the art. In this regard, reference can be made, for example, to S.Murosaki, et al. (1998) J.AllergyClin.Immunol.102(1):57-64 and S.Segawa, et al. (2008) Int.J.FoodMicrobiol.128(2):371-377.
[0035] Preferably, the heat inactivation is performed by heating at 60°C to 140°C for 1 second to 30 minutes. In a preferred embodiment of the present invention, the heat inactivation is performed by heating at 73±2°C for 15 seconds.
[0036] According to the present invention, Bacillus coagulans CB85 and Lactobacillus plantarum CB102 may be further subjected to a drying treatment. The drying treatment may be performed by a technique well known and commonly used by those skilled in the art, including, but not limited to, spray-drying treatment, lyophilization treatment, vacuum evaporation treatment, and combinations thereof. In a preferred embodiment of the present invention, Bacillus coagulans CB85 and Lactobacillus plantarum CB102 are subjected to a spray-drying treatment.
[0037] According to the present invention, Bacillus coagulans CB85 and Lactobacillus plantarum CB102 may be subjected to a separation process to remove the culture medium before being subjected to the drying process.
[0038] Preferably, the separation treatment is selected from the group consisting of: centrifugation treatment, filtration treatment, and combinations thereof. In a preferred embodiment of the present invention, the separation treatment is centrifugation treatment.
[0039] According to the present invention, the condition associated with SARS-CoV-2 infection is selected from the group consisting of: lung inflammation [including pneumonia and pulmonary infiltrates], lung injury [including acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD)], lymphopenia, abnormalities of granulocytes, immune escape (immunescape) [also known as immune evasion], cytokine storm (also known as cytokine storm), multisystem inflammatory syndrome (MIS) [including multisystem inflammatory syndrome in children (MIS-C) and multisystem inflammatory syndrome in adults (MIS-A)], and combinations thereof.
[0040] According to the present invention, the composition can be a food composition, for example, in the form of a food additive, which can be added to an edible material to prepare a food product for human or animal consumption. According to the present invention, the types of the food product can include, but are not limited to: milk powder, fermented milk, yogurt, butter, beverages (e.g., tea, coffee), functional beverages, flour products, baked foods, confectionery, candies, fermented foods, animal feeds, health foods, and dietary supplements.
[0041] According to the present invention, the food product may further comprise a food additive widely used in food manufacturing technology, including, but not limited to: starch, dextrin, lactose, maize flour, rice flour, tricalcium phosphate, silicon dioxide, magnesium stearate, calcium carbonate, glucose, sucrose, fructose, sugar alcohol, oligosaccharide, sugar substitute, fruit juice powder, yeast powder, nonfat dry milk, casein, whey protein, amino acid, citric acid, citrate, lactic acid, lactate and nucleotide.
[0042] According to the present invention, the composition may be a pharmaceutical composition.
[0043] According to the present invention, the pharmaceutical composition can be manufactured into a dosage form suitable for oral administration using techniques known to those skilled in the art, including, but not limited to, sterile powders, tablets, troches, lozenges, pellets, capsules, dispersible powders or granules, solutions, suspensions, emulsions, syrups, elixirs, slurries and the like. Preferably, the pharmaceutical composition is manufactured into a dosage form suitable for administration in capsules.
[0044] According to the present invention, the pharmaceutical composition may further include a pharmaceutically acceptable carrier widely used in drug manufacturing technology. For example, the pharmaceutically acceptable carrier may include one or more agents selected from the following: solvent, buffer, emulsifier, suspending agent, decomposer, disintegrating agent, dispersing agent, binding agent, excipient, stabilizer, chelating agent, diluent, gelling agent, preservative, wetting agent, lubricant, absorption delaying agent, liposome and the like. The selection and amount of these agents fall within the professional qualities and routine technical scope of those skilled in the art.
[0045] The present invention provides a method for improving conditions associated with SARS-CoV-2 infection, comprising administering a combination as described above to a subject in need thereof.
[0046] As used herein, the terms "administration" and "administration" are used interchangeably and refer to introducing, providing or delivering a predetermined active ingredient to a subject by any appropriate route to perform its intended effect.
[0047] As used herein, the term "subject" means any mammal of interest, such as humans, monkeys, cows, sheep, horses, pigs, goats, dogs, cats, mice, and rats.
[0048] According to the present invention, the dosage and frequency of administration of the combination of probiotics and postbiotics will vary depending on the severity of the disease to be improved, the route of administration, and the weight, age, physical condition and response of the individual to be improved. Generally speaking, the combination can be administered orally in the form of a single dose or divided into multiple doses.
[0049] The present invention will be further described with reference to the following examples. However, it should be understood that the examples are only for illustration and should not be construed as limitations on the implementation of the present invention.
[0050] <Example>
[0051] General experimental materials:
[0052] 1. Probiotic strains:
[0053] Bacillus coagulans CB85 and Lactobacillus plantarum CB102 used in the following examples are obtained from the Microbiology Laboratory of the Department of Food Science and Biotechnology at Chung Hsing University, and have been deposited in the Bioresource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) in Taiwan, China (300 No. 331, Food Road, Hsinchu City, Taiwan, China), and are publicly available. In addition, the probiotic strains are also deposited in the German Microbiological Collection Center (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, DSMZ) according to the provisions of the Budapest Treaty. For clarity, the relevant information of each probiotic strain (including: deposit number and deposit date, etc.) has been integrated in the following Table 1.
[0054] Table 1 Relevant information of each probiotic strain
[0055]
[0056] 2. Preparation of live Bacillus coagulans CB85 powder:
[0057] First, the Bacillus coagulans CB85 described in the first item above was inoculated into MRS broth medium (trade name: BD Difco Lactobacilli MRS Broth, catalog number: DF0881-17-5), and cultured at 37°C for 16 hours to obtain a bacterial solution of Bacillus coagulans CB85. After counting the number of bacteria using a plate count medium, the obtained bacterial solution of Bacillus coagulans CB85 was centrifuged at 10,000 rpm at 25°C for 15 minutes. After the supernatant was removed, the obtained pellets were subjected to spray-drying treatment to obtain live bacterial powder of Bacillus coagulans CB85 (having a concentration of 1×10 9 CFU / g bacterial concentration).
[0058] 3. Preparation of heat-inactivated Lactobacillus plantarum CB102 powder:
[0059] First, the plant lactobacillus CB102 described in item 1 above is inoculated into MRS broth medium (trade name BD Difco Lactobacilli MRS Broth, catalog number DF0881-17-5), and cultured at 37°C for 16 hours to obtain a bacterial solution of plant lactobacillus CB102. After counting the number of bacteria using a plate counting medium, the obtained plant lactobacillus CB102 bacterial solution is heat inactivated at 73±2°C for 15 seconds using a high temperature short time (HTST) process, followed by centrifugation at 10,000 rpm for 15 minutes at 25°C. After the supernatant is removed, the obtained precipitate is spray dried to obtain a heat-inactivated plant lactobacillus CB102 powder (having 5×10 9 CFU / g bacterial concentration).
[0060] 4. Experimental Animals:
[0061] Female BALB / c mice (8 weeks old, weighing about 20±1 g) used in the following examples were purchased from Lesco Biotech Co., Ltd. (located in Taipei, Taiwan, China). All experimental animals were housed in an independently air-conditioned animal room with 12 hours of light and 12 hours of darkness, room temperature maintained at 22±1°C, and relative humidity maintained at 55±5%, and water and feed were adequately supplied. The animal husbandry environment, treatment, and all experimental procedures were in accordance with the Institutes of Health's Guide for the Care and Use of Laboratory Animals (2011).
[0062] 5. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus strain used in the following examples was obtained from SIDSCO Biomedical Co., Ltd.
[0063] General experimental methods:
[0064] 1. Statistical analysis:
[0065] In the following examples, the experiments of each group were repeated 3 times, and the experimental data were expressed as "mean ± standard error of the mean (SEM)". All data were analyzed by independent sample t-test to evaluate the differences between the groups. If the statistical analysis results obtained were p < 0.05, it indicated statistical significance.
[0066] Example 1. Evaluation of the efficacy of the combination of live Bacillus coagulans CB85 and heat-inactivated Lactobacillus plantarum CB102 in improving SARS-CoV-2-induced lung injury and immune abnormalities
[0067] Experimental Materials:
[0068] 1. Preparation of live Bacillus coagulans CB85 and heat-killed Lactobacillus plantarum
[0069] CB102 Combinations:
[0070] The live bacterial powder of Bacillus coagulans CB85 obtained in items 2 and 3 of the above "General Experimental Materials" was mixed with the powder of heat-killed Lactobacillus plantarum CB102 at a bacterial count ratio of 1:1.47, thereby obtaining a combination containing the powder of live Bacillus coagulans CB85 and the powder of heat-killed Lactobacillus plantarum CB102 (hereinafter referred to as the strain combination of the present invention).
[0071] Experimental methods:
[0072] A. Administration of the strain combination of the present invention and inoculation of SARS-CoV-2 virus strains:
[0073] First, female BALB / c mice were randomly divided into 6 groups (n=8 in each group), including 1 blank control group, 1 normal control group, 1 pathological control group, 1 experimental group and 2 comparative experimental groups (i.e. comparative experimental groups 1 and 2). Then, the live bacterial powder of Bacillus coagulans CB85 and the heat-inactivated bacterial powder of Lactobacillus plantarum CB102 obtained in the 2nd and 3rd items of the above "general experimental materials" and the combination of strains of the present invention obtained in the 1st item of the above "experimental materials" were mixed in reverse osmosis water and orally administered to the mice of the normal control group, the experimental group and each comparative experimental group by oral gavage according to the dosage shown in Table 2 below. The administration was once a day for a total of 18 days. The mice in the blank control group and the pathological control group were not treated in any way.
[0074] Table 2 The strains and doses (CFU / day) administered orally to each group of mice
[0075]
[0076] a: The dosage of the strains was half of that in the comparative experimental group.
[0077] After the administration on the 15th day, the mice in the pathological control group, experimental group and each comparative experimental group were infected with 10 6 TCID 50 The mice in the blank control group and the normal control group were not treated in any way.
[0078] B. Pulmonary function test:
[0079] After the completion of dosing on day 15 and before inoculation with the SARS-CoV-2 virus strain, and after the completion of dosing on days 16, 17, and 18, the following respiratory parameters were measured by Buxco Whole Body Plethysmography (WBP) (DSI Buxco) to evaluate their lung function: enhanced pause (Penh), mid-tidal expiratory flow (EF50), and the ratio of time to peak expiratory flow (Rpef). The lower the measured Penh and EF50 and the higher the Rpef, the better the respiratory function.
[0080] Afterwards, the obtained experimental data were analyzed according to the method described in item 1 of the above “General Experimental Methods”.
[0081] C. Analysis of white blood cell content in bronchoalveolar lavage fluid (BALF):
[0082] After the administration on the 18th day, the mice in the blank control group, pathological control group, experimental group and each comparative experimental group were sacrificed, and then 1 mL of phosphate buffered saline (PBS) was injected into the lungs through the trachea of each group of mice using a bronchoscope, and the injected liquid was collected. The BALF obtained was centrifuged at 3,000 rpm for 10 minutes at 4°C, and the supernatant was collected and used for the analysis of item D below, and the formed precipitate was washed with PBS and resuspended in PBS. Afterwards, a hematology analyzer (IDEXX Laboratories, Inc., ProcyteDx) was used to count white blood cells, thereby obtaining the contents of total white blood cells, lymphocytes, neutrophils, eosinophils and basophils, respectively.
[0083] Afterwards, the obtained experimental data were analyzed according to the method described in item 1 of the above “General Experimental Methods”.
[0084] D. Determination of the concentration of inflammation-related factors in BALF:
[0085] The concentrations of IFN-γ, IL-4, IL-17 and IFN-β in the supernatant obtained in the above item C were measured using IFN-γ ELISA kit (brand: abcam, catalog number: ab100689), IL-4 ELISA kit (brand: abcam, catalog number: ab100710), IL-17 ELISA kit (brand: abcam, catalog number: ab100702) and IFN-β ELISA kit (brand: Elabscience, catalog number: E-EL-M0033) according to the manufacturer's instructions. The measured absorbance values were converted into their concentrations (pg / mL) according to the standard curves prepared in advance with standard samples of IFN-γ, IL-4, IL-17 and IFN-β with different known concentrations relative to their own absorbance values.
[0086] Afterwards, the obtained experimental data were analyzed according to the method described in item 1 of the above “General Experimental Methods”.
[0087] E. Histopathological examination of lung tissue:
[0088] After completing the analysis of items C and D above, the lung tissues of each group of mice were removed and fixed with 10% formalin at room temperature for 10 hours. The fixed tissue samples were then embedded in paraffin and sliced to obtain tissue sections with a thickness of 2-5 μm.
[0089] Afterwards, the obtained tissue sections were stained using hematoxylin-eosin and according to the techniques well known and commonly used by those skilled in the art, and then photographed using an optical microscope at a magnification of 100-400 times, and then commissioned a pathologist from Chung Hsing University to refer to the method described in HK Bayes, et al. (2016) Sci. Rep. doi: 10.1038 / srep35838 to evaluate the severity of lung damage [including edema, alveolar and interstitial inflammation, alveolar and interstitial hemorrhage, atelectasis, and hyaline membrane formation, etc.], and expressed on a scale of 1 to 4, with a higher score indicating a larger area of lung damage.
[0090] Afterwards, the obtained experimental data were analyzed according to the method described in item 1 of the above “General Experimental Methods”.
[0091] result:
[0092] A. Pulmonary function test:
[0093] Figures 1 to 3 The changes of Penh, EF50 and Rpef measured in each group of mice over time are shown respectively. Figures 1 to 3 It can be seen that there is no statistical difference in Penh, EF50 and Rpef between the blank control group and the normal control group, which means that the strain combination of the present invention will not affect the lung function of normal mice. Compared with the blank control group, the Penh and EF50 of the pathological control group will increase rapidly with the increase of time, while Rpef will decrease rapidly with the increase of time, which means that SARS-CoV-2 will harm the lung function and cause airway obstruction. Compared with the pathological control group, the increase in Penh and EF50 and the decrease in Rpef in the experimental group have been significantly reduced, and are also better than those in the comparative experimental groups 1 and 2. In particular, there is no statistical difference between the EF50 and Rpef of the comparative experimental group 1 and those of the pathological control group, and there is no statistical difference between the EF50 of the comparative experimental group 2 and those of the pathological control group. These experimental results show that the strain combination of the present invention can effectively improve the lung function of mice, and its efficacy is significantly better than that of using live Bacillus coagulans CB85 or heat-killed Lactobacillus plantarum CB102 alone.
[0094] B. Analysis of white blood cell content in BALF:
[0095] Figures 4 to 8 The total leukocyte, lymphocyte, neutrophil, eosinophil and basophil contents in BALF of each group of mice are shown respectively. Figures 4 to 8 It can be seen that compared with the blank control group, the total white blood cell and neutrophil contents measured in the pathological control group were significantly increased, while the contents of lymphocytes, eosinophils and basophils were significantly decreased, which means that SARS-CoV-2 can cause lymphopenia and abnormalities of granulocytes in mice. Compared with the pathological control group, the total white blood cell and neutrophil contents measured in the experimental group and comparative experimental groups 1 and 2 were significantly decreased, while the contents of lymphocytes, eosinophils and basophils were significantly increased. In particular, the total white blood cell and neutrophil contents measured in the experimental group were significantly lower than those measured in each comparative experimental group, and the contents of lymphocytes, eosinophils and basophils were also significantly higher than those measured in each comparative experimental group. These experimental results show that the strain combination of the present invention is significantly more effective than the live Bacillus coagulans CB85 or the heat-killed Lactobacillus plantarum CB102 alone in improving lymphocytopenia and abnormal granulocytes.
[0096] C. Determination of the concentration of inflammation-related factors in BALF:
[0097] Figures 9 to 12 The contents of IFN-γ, IL-4, IL-17 and IFN-β measured in BALF of each group of mice are shown respectively. Figures 9 to 12 It can be seen that compared with the blank control group, the levels of IFN-γ, IL-4 and IL-17 measured in the pathological control group were significantly increased, while the level of IFN-β was significantly decreased, which means that SARS-CoV-2 can induce lung inflammation in mice. Compared with the pathological control group, the levels of IFN-γ, IL-4 and IL-17 measured in the experimental group and comparative experimental groups 1 and 2 were significantly decreased, while the level of IFN-β was significantly increased. In particular, the levels of IFN-γ, IL-4 and IL-17 measured in the experimental group were significantly lower than those measured in each comparative experimental group, and the level of IFN-β was also significantly higher than that measured in each comparative experimental group. These experimental results show that the effect of the strain combination of the present invention on improving lung inflammation is significantly better than using live Bacillus coagulans CB85 or heat-killed Lactobacillus plantarum CB102 alone.
[0098] D. Histopathological examination of lung tissue:
[0099] Fig.13 The pathological scores of the lung tissues of mice in each group were observed by hematoxylin-eosin staining. Fig.13 It can be seen that compared with the blank control group, the pathological score of the pathological control group increased significantly, indicating that SARS-CoV-2 can induce lung damage in mice. Compared with the pathological control group, the pathological scores of the experimental group and the comparative experimental groups 1 and 2 were significantly reduced, especially the pathological scores of the experimental group were significantly lower than those of the comparative experimental groups. This experimental result shows that the effect of the strain combination of the present invention on improving lung damage is significantly better than using live Bacillus coagulans CB85 or heat-killed Lactobacillus plantarum CB102 alone.
[0100] Based on the above experimental results, it can be seen that compared with the use of live Bacillus coagulans CB85 or heat-inactivated Lactobacillus plantarum CB102 alone, the combination of the two at half the dose of the present invention can unexpectedly show better efficacy in improving lung inflammation and lung injury and immune abnormalities induced by SARS-CoV-2. Therefore, the combination is expected to be used to improve the conditions associated with SARS-CoV-2 infection, including immune escape and cytokine storm.
[0101] All patents and references cited in this specification are incorporated herein by reference in their entirety. In the event of a conflict, the detailed description (including definitions) of this specification will prevail.
[0102] Although the present invention has been described with reference to the above specific embodiments, it is apparent that many modifications and variations can be made without departing from the scope and spirit of the invention. It is therefore intended that the present invention be limited only as indicated by the appended claims.
Claims
1. A combination of probiotics and postbiotics for use in preparing a composition for improving conditions associated with SARS-CoV-2 infection, Features: The combination contains live Bacillus coagulans CB85 (DSM 33893) and heat-killed Lactobacillus plantarum CB102 (DSM 33894).
2. The use according to claim 1, Features: The bacterial count ratio of Bacillus coagulans CB85 to Lactobacillus plantarum CB102 is in a range of 1:0.1 to 1:
10.
3. The use according to claim 1, Features: The condition associated with SARS-CoV-2 infection is selected from the group consisting of: lung inflammation, lung damage, lymphocytopenia, granulocyte abnormalities, immune escape, immune storm, multisystem inflammatory syndrome, and combinations thereof.
4. The use according to claim 1, Features: The composition is a food composition.
5. The use according to claim 1, Features: The composition is a pharmaceutical composition.
6. The use according to claim 5, Features: The pharmaceutical composition is in a dosage form for oral administration.
